vertex pharmaceuticals - Search News

FDA, Vertex

Hosted on MSN · 40m

Vertex Pharmaceuticals Stock Jumps After FDA Approval for New Non-Opioid Painkiller

Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more than 20 years.

MarketWatch · 3h

Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.

Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved the company’s non-opioid pain treatment.

The Associated Press on MSN · 37m

FDA approves painkiller designed to eliminate risk of opioids addiction

WASHINGTON (AP) — Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and OxyContin. The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows surgery or injuries.

17mon MSN

These Stocks Are Moving the Most Today: Apple, Intel, Visa, Deckers, Atlassian, Vertex, Chevron, and More

Wall Street also was waiting to see whether President Donald Trump would follow through on his pledge to enact tariffs on ...

1h

Vertex Pharmaceuticals’ JOURNA VX: Navigating Market Challenges Despite Promising Financial Outlook

Needham analyst Joseph Stringer has maintained their neutral stance on VRTX stock, giving a Hold rating today.Invest with Confidence: Follow ...

Vertex Pharmaceuticals Stock Soars as Non-Opiod Pain Treatment Gets FDA Nod

Vertex Pharmaceuticals' newly FDA-approved non-opioid analgesic, Journavx, offers a groundbreaking alternative for managing ...

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

1h

Cautious Outlook on Vertex Pharmaceuticals Amid Journavx Approval and Pricing Concerns

Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results